Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exscientia plc
Exscientia Business Update for Second Quarter and First Half 2024
August 15, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
July 18, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
July 10, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology
June 06, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at Upcoming Investor Conferences in June
May 30, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for First Quarter 2024
May 21, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024
May 14, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business and Financial Update for the Full Year 2023
March 21, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
March 14, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at Upcoming Investor Conferences in March
February 28, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
February 07, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
December 21, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
December 05, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for Third Quarter 2023
November 09, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023
November 02, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Parker Moss to Join Exscientia as EVP, Corporate Development
October 17, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
October 16, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Details Pipeline Prioritisation Strategy
October 03, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
September 20, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at Upcoming Investor Conferences in September
August 31, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for Second Quarter and First Half of 2023
August 10, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
July 10, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for First Quarter 2023
May 24, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
May 22, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
May 17, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
May 15, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
May 03, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
April 19, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.